advertisement
11.4 Prostaglandins (27)
Showing records 1 to 25
Display all abstracts in classification 11.4 Prostaglandins
Search within classification 11.4 Prostaglandins20611 Increase and decrease of measurements of iris density of glaucoma patients treated with latanoprost over 36 months
Schwartz B; Takamoto T; Martin J
Journal of Ocular Pharmacology and Therapeutics 2008; 24: 94-103
20547 Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma
Gupta SK; Agarwal R; Galpalli ND; Srivastava S; Agrawal SS; Saxena R
Methods and Findings in Experimental and Clinical Pharmacology 2007; 29: 665-671
20445 The Effect of Latanoprost, Bimatoprost, and Travoprost on Circadian Variation of Intraocular Pressure in Patients With Open-angle Glaucoma
Yildirim N; Sahin A; Gultekin S
Journal of Glaucoma 2008; 17: 36-39
20405 Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma
Costagliola C; Parmeggiani F; Virgili G; Lamberti G; Incorvaia C; Perri P; Campa C; Sebastiani A
Graefe's Archive for Clinical and Experimental Ophthalmology 2008; 246: 389-396
20843 First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study
Gherghel D; Hosking SL; Cunliffe IA; Armstrong RA
Eye 2008; 22: 363-369
20618 Comparison of the effects of latanoprost and bimatoprost on intraocular pressure in chronic angle-closure glaucoma
Chen M-J; Chen Y-C; Chou C-K; Hsu W-M
Journal of Ocular Pharmacology and Therapeutics 2007; 23: 559-565
20620 Bilateral severe fibrinous anterior uveitis - An unusual complication of pamidronate therapy exacerbated by topical latanoprost
Ramasamy B; Quah S; Sahni JN; Palimar P
Journal of Ocular Pharmacology and Therapeutics 2007; 23: 513-515
20617 Cystoid macular edema in a pseudophakic patient after switching from latanoprost to BAK-free travoprost
Esquenazi S
Journal of Ocular Pharmacology and Therapeutics 2007; 23: 567-569
20328 Enhancing trabecular outflow by disrupting the actin cytoskeleton, increasing uveoscleral outflow with prostaglandins
Kaufman PL
Experimental Eye Research 2008; 86: 3-17
20330 The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review
Hodge WG; Lachaine J; Steffensen I; Murray C; Barnes D; Foerster V; Ducruet T; Morrison A
British Journal of Ophthalmology 2008; 92: 7-12
20506 A 6-Week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clinical Therapeutics 2007; 29: 1915-1923
20821 Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe
Stewart WC; Stewart JA; Nelson LA; Kruft B
European Journal of Ophthalmology 2008; 18: 199-204
20388 Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment
Konstas AG; Kozobolis VP; Tsironi S; Makridaki I; Efremova R; Stewart WC
Ophthalmology 2008; 115: 99-103
20757 Latanoprost does not affect immune privilege of corneal allografts
Wang M; Kitahara Y; Yoshida A; Hori J
Experimental Eye Research 2008; 86: 394-402
20646 Changes of the thickness of the ciliary body after the latanoprost 0.005 % application
Vyborny P; Hejsek L; Sicakova S; Pasta J
Česka a Slovenska Oftalmologie 2007; 63: 415, 418-421
20358 Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments
Bahler CK; Howell KG; Hann CR; Fautsch MP; Johnson DH
American Journal of Ophthalmology 2008; 145: 114-119
20321 The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy
Sharpe ED; Reynolds AC; Skuta GL; Jenkins JN; Stewart WC
Current Eye Research 2007; 32: 1037-1043
20778 Quality of diurnal intraocular pressure control in primary open-angle patients treated with latanoprost compared with surgically treated glaucoma patients: a prospective trial
Mansouri K; Orguel S; Mermoud A; Haefliger I; Flammer J; Ravinet E; Shaarawy T
British Journal of Ophthalmology 2008; 92: 332-336
20312 The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension
Arcieri ES; Pierre Filho PT; Wakamatsu TH; Costa VP
Eye 2008; 22: 179-183
20475 Prostamides (prostaglandin-ethanolamides) and their pharmacology
Woodward DF; Liang Y; Krauss AH-P
British Journal of Pharmacology 2008; 153: 410-419
20805 A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients
Alagoz G; Gürel K; Bayer A; Serin D; Celebi S; Kukner S
Ophthalmologica 2008; 222: 88-95
20613 Effect of topical prostaglandin analog use on outcome following selective laser trabeculoplasty
Scherer WJ
Journal of Ocular Pharmacology and Therapeutics 2007; 23: 503-512
20531 Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: Analysis conducted on the United Kingdom General Practitioner Research Database
Lafuma A; Berdeaux G
Current Medical Research and Opinion 2007; 23: 3009-3016
20689 Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension.
Frenkel RE; Frenkel M; Toler A
BMC Ophthalmology 2007; 7: 16
20310 Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis
Lachaine J; Hodge WG; Steffensen I; Murray C; Barnes D; Foerster V; Ducruet T; Mensinkai S
Canadian Journal of Ophthalmology 2008; 43: 33-41